Alzheimer‘s Disease, Cognitive Impairment
Conditions
Interventions
VR + Meditation Group:Wear HTC VIVE Cosmos VR headset, use immersive VR combined with Kirtan Kriya meditation rehabilitation software system developed based on Unreal Engine 4. The system plays highli
Sham VR + Meditation Group:Wear VR headset, given prior instructions on meditation steps, no audiovisual playback, self-guided meditation. 5 times per week, 30 minutes each session, for a total of 8 w
Sponsors
The Second Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Age >= 50 years old and =10 points, GDS 3-5 (i.e., included patients with early and middle stage Alzheimer's disease); 7.Donepezil hydrochloride was used for standardized treatment without other intervention means; 8.The patient has a regular caregiver who is willing to accompany the patient to treatment every day; 9.Agree to participate in this clinical trial, willing to maintain the original treatment plan during the trial, and have signed the informed consent. 10. Gender not specified;
Exclusion criteria
Exclusion criteria: 1.Any major neurological disease suspected of being outside the early stages of Alzheimer's disease, such as Parkinson's disease, vascular dementia, Huntington's disease, hydrocephalus, brain tumors, progressive supranuclear palsy, seizures, subdural hematoma, multiple sclerosis, or a history of major head trauma with persistent neurological deficits or known brain structural abnormalities; 2.Elderly patients with other complex or serious underlying diseases, such as severe arrhythmia, severe respiratory dysfunction, and severe acute abdomen; 3. Patients with hepatitis A, hepatitis B, AIDS, tuberculosis and other infectious diseases, and are currently active; 4.Subjects with severe visual or hearing impairment; 5.Subjects with major depressive disorder, bipolar disorder, or schizophrenia in the past 1 year; 6.Subjects currently receiving medication for obsessive-compulsive disorder or attention deficit disorder; 7.Those who are alcohol dependent, addicted to drugs or other drugs or have a tendency to be; 8.Those who have participated in other drug trials within the past 8.2 months; 9. Subjects with contraindications for magnetic resonance imaging include those with pacemakers, metal fragments, foreign objects in the eyes, skin, or body, or patients with claustrophobia, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mini-Mental State Examination (MMSE);Montreal Cognitive Assessment (MoCA);Mind Wandering Self-Report Scale (Free-Running and Spontaneous Mind Wandering Tasks);Activities of Daily Living (ADL) Scale;Brief Profile of Mood States (BPOMS);Hamilton Anxiety Rating Scale (HAMA);Hamilton Depression Rating Scale (HAMD);Plasma Total Tau Protein;Plasma Neurofilament Light Chain (NFL);Plasma AD7cNTP Protein;Functional MRI (fMRI) Assessment (Default Network Brain Regions, White Matter Network Small-World Properties, Network Efficiency, Node Attributes, and Core Nodes); | — |
Countries
China
Contacts
Public ContactTu Wenxian
The Second Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed